GPhC reveals draft criteria to cut record number of fitness-to-practise concerns The General Pharmaceutical Council said that concerns raised have doubled over the past five years, from 2,989 in 2020/2021 to 6,202 in 2024/2025.…
Yellow Card reporting to be taught across schools in England The Medicines and Healthcare products Regulatory Agency's Yellow Card scheme enables people to report an adverse event or side effect relating to medicines and medical devices in the UK.…
Investigations ongoing as regulator takes action against Jhoots The General Pharmaceutical Council's enforcement action against Jhoots follows concerns raised about unexpected closures and ‘poor service’ in several branches.…
MHRA approves first new UTI antibiotic in 30 years Gepotidacin (Blujepa; GSK) is approved for the treatment of uncomplicated UTIs in patients aged 12 years and over, who weigh at least 40kg.…
‘Sub-therapeutic’ dose of antipsychotic contributed to patient death, coroner finds An area coroner for Essex has expressed concerns over a female patient’s management.…
MHRA approves UK’s first immunotherapy for type 1 diabetes Teplizumab (Tzield; Sanofi) has been approved by the MHRA for delaying the progression of type 1 diabetes mellitus.…
GPhC warns of emerging patient safety issues In a letter to pharmacists, pharmacy technicians and pharmacy owners, Roz Gittins has highlighted concerns reported to the regulator and the importance of ensuring safe and effective pharmacy care for patients.…
Only one in ten people report side effects, Healthcare Improvement Scotland warns Healthcare Improvement Scotland is calling for greater awareness of the Yellow Card scheme, as too few patients report medication side effects.…
GPhC chief executive to step down after 15 years in post Duncan Rudkin has served as chief executive of the General Pharmaceutical Council since the regulator was established in 2010.…
MHRA ‘shares concerns’ over failure to meet epilepsy drug prescribing target Exclusive: Alison Cave, chief safety officer at the MHRA, has echoed concerns about persistent sodium valproate prescribing raised by the Independent Fetal Anti-Convulsant Trust.…
